RIM
NBIX icon

RS Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

RS Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$504K Hold
11,090
– – 0.01% 342
2016
Q1 		$439K Sell
11,090
-598,860
-98% -$23.8M ﹤0.01% 339
2015
Q4 		$34.5M Sell
609,950
-229,010
-27% -$11.6M 0.31% 111
2015
Q3 		$33.4M Buy
838,960
+127,950
+18% +$6.18M 0.3% 120
2015
Q2 		$34M Buy
711,010
+114,130
+19% +$4.84M 0.29% 134
2015
Q1 		$23.7M Buy
+596,880
New +$21.4M 0.21% 169

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RS Investment Management's NBIX Position: Q2 2016 in Review

RS Investment Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2016 at 11,090 shares worth $504K. The position accounts for 0.01% of the portfolio, ranked #342.

RS Investment Management first reported a position in NBIX in Q1 2015 and has held it in 6 quarters since. The position peaked at $34.5M in Q4 2015. 232 funds tracked by Wall St. Rank hold NBIX as of Q2 2016.

  • RS Investment Management held 11,090 shares of Neurocrine Biosciences worth $504K as of Q2 2016.
  • RS Investment Management left its Neurocrine Biosciences share count unchanged in Q2 2016.
  • Neurocrine Biosciences made up 0.01% of RS Investment Management's portfolio in Q2 2016, its #342 holding.
  • RS Investment Management first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 6 quarters since.
  • RS Investment Management's Neurocrine Biosciences position peaked at $34.5M in Q4 2015.
  • 232 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2016.

Based on RS Investment Management's 13F filing for Q2 2016, filed 26 Jul 2016.